Rifkin, R. M., Abonour, R., Shah, J. J., Mehta, J., Narang, M., Terebelo, H., … Durie, B. G. M. (2016). Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide. Leuk Lymphoma, 57(9), 2228–2231. https://doi.org/10.3109/10428194.2015.1132419

Rifkin, Robert M., Rafat Abonour, Jatin J. Shah, Jayesh Mehta, Mohit Narang, Howard Terebelo, Cristina Gasparetto, et al. “Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide.” Leuk Lymphoma 57, no. 9 (September 2016): 2228–31. https://doi.org/10.3109/10428194.2015.1132419.

Rifkin RM, Abonour R, Shah JJ, Mehta J, Narang M, Terebelo H, et al. Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide. Leuk Lymphoma. 2016 Sep;57(9):2228–31.

Rifkin, Robert M., et al. “Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide.” Leuk Lymphoma, vol. 57, no. 9, Sept. 2016, pp. 2228–31. Pubmed, doi:10.3109/10428194.2015.1132419.

Rifkin RM, Abonour R, Shah JJ, Mehta J, Narang M, Terebelo H, Gasparetto C, Toomey K, Hardin JW, Lu JJ, Kenvin L, Srinivasan S, Knight R, Nagarwala Y, Durie BGM. Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide. Leuk Lymphoma. 2016 Sep;57(9):2228–2231.